Thyroid & Weight

Thyroid disease intersects obesity care with multiple commonly-believed myths needing evidence-based clarification. The session covers hypothyroidism and weight gain myths (small effect, modest reversibility), levothyroxine adjustment after weight loss, subclinical hypothyroidism management debate, post-bariatric thyroid changes, thyroid cancer surveillance after rapid weight loss, and the role of thyroid hormone analogues in obesity (resmetirom as the THR-β agonist exemplar). Discussion addresses Hashimoto thyroiditis prevalence, the comparison of T4 monotherapy vs T4/T3 combination, thyroid hormone replacement in obesity vs lean, hyperthyroidism and weight, and emerging thyroid-targeted obesity therapeutics.